Case Studies

Bellus Health (NASDAQ: BLU) Investor Relations Program

October 19, 2022

BACKGROUND Bellus Health is a clinical-stage biopharmaceutical company focused on developing a P2X3 antagonist to address refractory chronic cough and other hypersensitization disorders. The Company’s lead candidate, BLU-5937, is a highly selective P2X3 antagonist currently being developed for the treatment of refractory chronic cough. LifeSci Advisors has been engaged to support Bellus Health with investor…

Read More

CinCor Pharma, Inc. (CINC): Successful IPO

September 23, 2022

BACKGROUND CinCor is a clinical-stage biopharmaceutical company focused on developing baxdrostat, a hypertension (HTN) drug for patients with resistant hypertension (rHTN) or uncontrolled hypertension (uHTN) with the goal of providing improved treatment for patients suffering from hypertension and not yet at goal. At the request of the CFO, LifeSci Advisors started working with CinCor a…

Read More

Vera (VERA): Investor Relations Program

July 6, 2022

LIFESCI’s ACTIVITIES Aggressive outreach to new investors and sell-side analysts Arranged 80 TTW and IPO roadshow meetings Arranged 13 meetings during the 2022 LifeSci Corporate Access Event Worked with management to strengthen messaging and optimize competitive positioning for MAU868 and other pipeline programs Organized two well-attended KOL events for ‘Ataciept’ and ‘MAU868’. Provided capital markets…

Read More

PharmaMar (PHM.BME): Investor Relations Program

June 7, 2022

Background PharmaMar is a commercial-stage oncology company headquartered in Spain and listed on the Bolsas y Mercados Españoles exchange. Despite the successful commercial launch of PharmaMar’s product Zepzelca® (lurbinectedin) in 2020 by partner Jazz Pharmaceuticals as a second-line treatment for SCLC, the Zepzelca® story struggled to gain traction with investors and the broader PharmaMar investment…

Read More

Valneva NASDAQ IPO (Dual-Listing) Case Study

May 20, 2022

In preparation for a near-term NASDAQ IPO, Valneva sought to capitalize on the numerous catalysts expected over the course of 2021 from its pipeline of promising COVID-19, Lyme Disease, and Chikungunya vaccines. LifeSci worked to raise Valneva’s visibility among the investment community and position Valneva for a successful US dual-listing and global equity offering.  …

Read More

Inspire Medical – KOL Event and Platform Drive Visibility Prior to IPO

October 12, 2021

Inspire Medical became a LifeSci Advisors client pre-IPO. The teams collaborated to develop and execute a robust, best-in-class investor relations program to engage the investment community The Process A successful strategically timed KOL event before going live on the IPO was well attended by investors and sell-side analysts, attracting potential investors new to the story…

Read More